Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.
One of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death. The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.
The latest trend gaining momentum in the market is growing investments from venture capitalists. Venture capitalists are capitalizing on the need for effective treatment and are offering therapeutic treatment solutions to treat disorders such as autoimmune disorders, infections, and cancer.
In 2018, the global Human Microbiome Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Human Microbiome Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Microbiome Therapeutics development in United States, Europe and China.
The key players covered in this study
Johnson & Johnson
Market segment by Type, the product can be split into
Market segment by Application, split into
Inflammatory Bowel Disease
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Human Microbiome Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Human Microbiome Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Human Microbiome Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.